On October 30, the Grupo Profarma announced the resumption of Profarma Specialty operations, reaffirming its commitment to excellence in the distribution of highly complex and value-added products. Profarma Specialty specializes in the marketing and distribution of vaccines, highly complex medicines, and injectable aesthetic products, focusing on innovation, safety, and quality in meeting the demands of the health and wellness market.
With the return of the business unit, the Grupo Profarma reinforces its strategy of expanding its presence in specialized niches, strengthening its relationship with laboratories, clinics, hospitals, and healthcare professionals. Profarma Specialty will now be integrated in an even more synergistic way, benefiting from the Company’s logistics structure, credibility, and more than 60 years of experience in pharmaceutical distribution.
The initiative marks a new cycle of growth, supported by investments in technology, compliance, and operational excellence, with the goal of ensuring the efficient delivery of products that require specific storage, transportation, and traceability precautions.
“Profarma Specialty represents our commitment to innovation and specialization in strategic healthcare segments. Its resumption strengthens the Grupo Profarma position as a benchmark in comprehensive solutions for the pharmaceutical and medical-hospital market,” said Vilson Schvartzman, vice president of Profarma Specialty.
With this, the Company strengthens its mission to contribute to safe and efficient access to therapies and products that positively impact people’s health and quality of life.